Free Trial
NYSEAMERICAN:NBY

NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis

NovaBay Pharmaceuticals logo
$1.20 -0.03 (-2.44%)
Closing price 10/13/2025 04:10 PM Eastern
Extended Trading
$1.16 -0.03 (-2.92%)
As of 06:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About NovaBay Pharmaceuticals Stock (NYSEAMERICAN:NBY)

Advanced

Key Stats

Today's Range
$1.16
$1.28
50-Day Range
$0.58
$4.22
52-Week Range
$0.46
$4.44
Volume
218,878 shs
Average Volume
888,778 shs
Market Capitalization
$7.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$0.85
Consensus Rating
Buy

Company Overview

NovaBay Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
18th Percentile Overall Score

NBY MarketRank™: 

NovaBay Pharmaceuticals scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    NovaBay Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Downside Risk

    NovaBay Pharmaceuticals has a consensus price target of $0.85, representing about 29.2% downside from its current price of $1.20.

  • Amount of Analyst Coverage

    NovaBay Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about NovaBay Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for NovaBay Pharmaceuticals are expected to grow in the coming year, from ($2.54) to ($0.55) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NovaBay Pharmaceuticals is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NovaBay Pharmaceuticals is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about NovaBay Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    14.16% of the outstanding shares of NovaBay Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    NovaBay Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NovaBay Pharmaceuticals has recently decreased by 53.74%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    NovaBay Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    NovaBay Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.16% of the outstanding shares of NovaBay Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    NovaBay Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NovaBay Pharmaceuticals has recently decreased by 53.74%, indicating that investor sentiment is improving significantly.
  • Search Interest

    20 people have searched for NBY on MarketBeat in the last 30 days. This is an increase of 18% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added NovaBay Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NovaBay Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    20.10% of the stock of NovaBay Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 23.25% of the stock of NovaBay Pharmaceuticals is held by institutions.

  • Read more about NovaBay Pharmaceuticals' insider trading history.
Receive NBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NBY Stock News Headlines

Buy alert: Move $1,000 before Tesla’s Optimus launch
Elon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's preparing for a "mind blowing" new launch that could see Tesla move away from electric cars... and into a new market.tc pixel
See More Headlines

NBY Stock Analysis - Frequently Asked Questions

NovaBay Pharmaceuticals' stock was trading at $0.58 at the start of the year. Since then, NBY stock has increased by 106.9% and is now trading at $1.20.

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) issued its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.32. The biopharmaceutical company earned $2.44 million during the quarter, compared to the consensus estimate of $2.50 million.

NovaBay Pharmaceuticals's stock reverse split on the morning of Friday, May 31st 2024.The 1-35 reverse split was announced on Friday, May 31st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 31st 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NovaBay Pharmaceuticals investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), Tesla (TSLA) and TherapeuticsMD (TXMD).

Company Calendar

Last Earnings
11/07/2024
Dividend Payable
9/15/2025
Dividend Payable
9/29/2025
Record date for 9/15 Dividend
9/29/2025
Ex-Dividend for 9/29 Dividend
9/30/2025
Record date for 9/29 Dividend
10/01/2025
Today
10/14/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEAMERICAN:NBY
Previous Symbol
AMEX:NBY
CIK
1389545
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$0.85
Low Price Target
$0.85
Potential Upside/Downside
-29.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($9.9465)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$7.22 million
Net Margins
N/A
Pretax Margin
-75.96%
Return on Equity
-297.77%
Return on Assets
-140.10%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.85
Quick Ratio
2.63

Sales & Book Value

Annual Sales
$9.78 million
Price / Sales
0.74
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.03) per share
Price / Book
-40.00

Miscellaneous

Outstanding Shares
6,010,000
Free Float
4,803,000
Market Cap
$7.21 million
Optionable
Not Optionable
Beta
0.62
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NYSEAMERICAN:NBY) was last updated on 10/14/2025 by MarketBeat.com Staff
From Our Partners